CLINICAL TRIALS PROFILE FOR OTEZLA
✉ Email this page to a colleague
All Clinical Trials for otezla
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Amgen | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
| NCT00521339 ↗ | Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis | Completed | Celgene Corporation | Phase 2 | 2007-08-01 | The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis. |
| NCT00773734 ↗ | Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | Completed | Amgen | Phase 2 | 2008-09-01 | The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it. |
| NCT00773734 ↗ | Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) | Completed | Celgene Corporation | Phase 2 | 2008-09-01 | The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it. |
| NCT00866359 ↗ | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | Completed | Amgen | Phase 2 | 2009-08-01 | The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease. |
| NCT00866359 ↗ | A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | Completed | Celgene Corporation | Phase 2 | 2009-08-01 | The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease. |
| NCT01194219 ↗ | Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis | Completed | Amgen | Phase 3 | 2010-09-09 | This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for otezla
Condition Name
Clinical Trial Locations for otezla
Trials by Country
Clinical Trial Progress for otezla
Clinical Trial Phase
Clinical Trial Sponsors for otezla
Sponsor Name
